This article is more than 5 years old. Information may no longer be current.

VIDEO: ASCO data highlights promise of bispecific antibodies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Venkateshwar “Venkat” Reddy, PhD, vice president and global head of translational science for Glenmark Pharmaceuticals, spoke with HemOnc Today at ASCO Annual Meeting about the company’s bispecific T-cell engager platform.

At ASCO, researchers presented preclinical and translational data on GBR 1302 (Glenmark), a HER-2 and CD3 bispecific antibody under investigation for treatment of a variety of HER-2-positive cancers.

“If you look at solid tumors, where some [chimeric antigen receptor T-cell therapies and checkpoint inhibitors] have not been effective, I think bispecific molecules are showing the promise where you can infiltrate these immune cells into the solid tumors and actually have an impact,” Reddy told HemOnc Today.

Investigators also presented a trial-in-progress poster about GBR 1342 (Glenmark), a CD38 and CD3 bispecific antibody under investigation for treatment of refractory multiple myeloma.